These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32087023)

  • 1. Treat to target and prevention of subclinical atherosclerosis in psoriatic arthritis-which target should we choose?
    Cheng IT; Li EK; Wong PC; Law MY; Yim IC; Lai BT; Ying SK; Kwok KY; Li M; Li TK; Lee JJ; Szeto CC; Yan BP; Lee AP; Tam LS
    Rheumatology (Oxford); 2020 Oct; 59(10):2881-2892. PubMed ID: 32087023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Achieving Minimal Disease Activity on the Progression of Subclinical Atherosclerosis and Arterial Stiffness: A Prospective Cohort Study in Psoriatic Arthritis.
    Cheng IT; Shang Q; Li EK; Wong PC; Kun EW; Law MY; Yip RM; Yim IC; Lai BT; Ying SK; Kwok KY; Li M; Li TK; Zhu TY; Lee JJ; Chang MM; Szeto CC; Yan BP; Lee AP; Tam LS
    Arthritis Rheumatol; 2019 Feb; 71(2):271-280. PubMed ID: 30144299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis.
    Wervers K; Vis M; Tchetveriko I; Gerards AH; Kok MR; Appels CWY; van der Graaff WL; van Groenendael JHLM; Korswagen LA; Veris-van Dieren JJ; Hazes JMW; Luime JJ
    Arthritis Care Res (Hoboken); 2018 Dec; 70(12):1764-1770. PubMed ID: 29609220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
    Lubrano E; De Socio A; Perrotta FM
    J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies.
    Schneeberger EE; Citera G; Nash P; Smolen JS; Mease PJ; Soriano ER; Helling C; Szumski AE; Mundayat R; de León DP
    Semin Arthritis Rheum; 2023 Feb; 58():152134. PubMed ID: 36476498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.
    Coates LC; Gladman DD; Nash P; FitzGerald O; Kavanaugh A; Kvien TK; Gossec L; Strand V; Rasouliyan L; Pricop L; Ding K; Jugl SM; Gaillez C;
    Arthritis Res Ther; 2018 Dec; 20(1):272. PubMed ID: 30526678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study.
    Coates LC; Nash P; Kvien TK; Gossec L; Mease PJ; Rasouliyan L; Pricop L; Jugl SM; Gandhi KK; Gaillez C; Smolen JS
    Semin Arthritis Rheum; 2020 Aug; 50(4):709-718. PubMed ID: 32521325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moderate and high disease activity levels increase the risk of subclinical atherosclerosis progression in early rheumatoid arthritis: a 5-year prospective study.
    Meng H; Cheng IT; Yan BPY; Lee AP; So H; Tam LS
    RMD Open; 2024 Jan; 10(1):. PubMed ID: 38199848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?
    Kilic G; Kilic E; Nas K; Kamanlı A; Tekeoglu İ
    Rheumatol Int; 2019 Jan; 39(1):73-81. PubMed ID: 30426235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial.
    Mease P; Husni ME; Kafka S; Chakravarty SD; Harrison DD; Lo KH; Xu S; Hsia EC; Kavanaugh A
    Arthritis Res Ther; 2020 Mar; 22(1):43. PubMed ID: 32143685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort.
    van Mens LJJ; van de Sande MGH; van Kuijk AWR; Baeten D; Coates LC
    Ann Rheum Dis; 2018 Feb; 77(2):251-257. PubMed ID: 29080861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries.
    Gorlier C; Orbai AM; Puyraimond-Zemmour D; Coates LC; Kiltz U; Leung YY; Palominos P; Cañete JD; Scrivo R; Balanescu A; Dernis E; Tälli S; Ruyssen-Witrand A; Soubrier M; Aydin SZ; Eder L; Gaydukova I; Lubrano E; Kalyoncu U; Richette P; Husni ME; de Wit M; Smolen JS; Gossec L
    Ann Rheum Dis; 2019 Feb; 78(2):201-208. PubMed ID: 30442648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value.
    Coates LC; Gottlieb AB; Merola JF; Boone C; Szumski A; Chhabra A
    J Rheumatol; 2019 Feb; 46(2):160-165. PubMed ID: 30323006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating current definitions of low disease activity in psoriatic arthritis using ultrasound.
    Bosch P; Husic R; Ficjan A; Gretler J; Lackner A; Graninger WB; Duftner C; Hermann J; Dejaco C
    Rheumatology (Oxford); 2019 Dec; 58(12):2212-2220. PubMed ID: 31199483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study.
    Coates LC; Mease PJ; Gladman DD; Navarra S; Bao W; Gaillez C
    RMD Open; 2023 Apr; 9(2):. PubMed ID: 37094983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis.
    Hagège B; Tan E; Gayraud M; Fautrel B; Gossec L; Mitrovic S
    Rheumatology (Oxford); 2020 Aug; 59(8):1818-1825. PubMed ID: 32118267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of subclinical atherosclerosis in psoriatic arthritis patients with minimal disease activity.
    Yilmazer B; Sahin T; Unlu BÖ; Kir HM; Cefle A
    Rheumatol Int; 2015 Aug; 35(8):1385-92. PubMed ID: 25669439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular risk reclassification according to six cardiovascular risk algorithms and carotid ultrasound in psoriatic arthritis patients.
    Galarza-Delgado DA; Azpiri-Lopez JR; Colunga-Pedraza IJ; Guajardo-Jauregui N; Rodriguez-Romero AB; Lugo-Perez S; Cardenas-de la Garza JA; Arvizu-Rivera RI; Flores-Alvarado DE; Ilizaliturri-Guerra O; Garcia-Arellano G; Garza-Acosta AC
    Clin Rheumatol; 2022 May; 41(5):1413-1420. PubMed ID: 34826020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis.
    Eder L; Thavaneswaran A; Chandran V; Cook R; Gladman DD
    Ann Rheum Dis; 2015 Oct; 74(10):1830-5. PubMed ID: 24827532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial.
    Helliwell PS; Deodhar A; Gottlieb AB; Boehncke WH; Xu XL; Xu S; Wang Y; Hsia EC; Gladman DD; Ritchlin CT
    Arthritis Care Res (Hoboken); 2020 Nov; 72(11):1579-1588. PubMed ID: 31421033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.